• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Roche and As­traZeneca set­tle years­long patent bat­tle over Ul­tomiris — re­port

4 years ago
Pharma

As Mod­er­na adds on a host of new com­mer­cial subs, there's room for 3 more vac­cine can­di­dates in the pipeline

4 years ago
R&D

Track­ing men­tal health: Lund­beck part­ner­ship de­buts US map­ping dash­board tool

4 years ago
Pharma
Marketing

J&J back in court over new gener­ic threat from In­tas, just months af­ter fend­ing off Te­va

4 years ago
Pharma

To keep up with de­mand, Sor­ren­to ac­quires ma­jor­i­ty own­er­ship in Covid-19 test man­u­fac­tur­er

4 years ago
Pharma
Manufacturing

One mi­cro­cap biotech is charg­ing head­first in­to treach­er­ous IPO wa­ters, jump­ing to Nas­daq with mod­est raise

4 years ago
Financing

FDA up­dates Mer­ck­'s Covid-19 pill EUA and reaf­firms it should on­ly be used as a last re­sort

4 years ago
FDA+
Coronavirus

Bay­er's next-gen drug Nube­qa aces sur­vival test in metasta­t­ic prostate can­cer, putting it in com­pe­ti­tion with gi­ants

4 years ago
R&D

FDA starts probe in­to a clin­i­cal tri­al death as next-gen CAR-T re­searchers stop en­roll­ment

4 years ago
Cell/Gene Tx
FDA+

Bio­Marin gene ther­a­py could be on hold 'for sev­er­al quar­ter­s' af­ter FDA man­dates new pre­clin­i­cal tests

4 years ago
R&D
Cell/Gene Tx

In sur­prise flop, Re­gen­eron, Sanofi re­port Dupix­ent PhI­II fail­ure, trig­ger­ing pre­ma­ture tri­al stop

4 years ago
R&D

Af­ter sell­ing off Tib­so­vo and en­tire can­cer pipeline, Agios nets first ap­proval for new 'an­chor pro­duc­t'

4 years ago
FDA+

Am­gen, Ipsen vet moves up the lad­der with Co­herus' an­ti-PD-1 await­ing PDU­FA; It takes a vil­lage to re­place Frank ...

4 years ago
Peer Review

Flash­ing red on RSV ma­ter­nal vac­cine, GSK paus­es PhI­II tri­al fol­low­ing ‘ob­ser­va­tion’ from safe­ty check

4 years ago
R&D

Am­gen qui­et­ly kills an obe­si­ty pro­gram, cast­ing bleak fu­ture for once-promis­ing tar­get

4 years ago
R&D
Discovery

Open sea­son on PBMs but FTC votes against dig­ging in­to their an­ti-com­pet­i­tive prac­tices fur­ther

4 years ago
R&D

GSK gets tem­po­rary re­strain­ing or­der against for­mer em­ploy­ee ac­cused of steal­ing trade se­crets

4 years ago
Pharma

Is the clock tick­ing on Mod­er­na's patent promise? Ac­tivists fear South African patents could hin­der vac­cine ...

4 years ago
Pharma
Coronavirus

As­traZeneca scores an­oth­er in­dus­try vic­to­ry over the fed­er­al gov­ern­ment in 340B lit­i­ga­tion

4 years ago
Pharma

Om­ni­pod gets in the game with di­a­betes-themed is­land in ‘An­i­mal Cross­ing’

4 years ago
Pharma
Marketing

Ther­mo Fish­er posts the help want­ed sign as it up­grades sin­gle-use man­u­fac­tur­ing ca­pac­i­ty in Penn­syl­va­nia for sec­ond ...

4 years ago
Pharma
Manufacturing

Pfiz­er's off the hook af­ter fed­er­al judge dis­miss­es pro­posed law­suit over Chan­tix re­calls

4 years ago
Pharma

US sen­a­tor blasts J&J's Texas two-step bank­rupt­cy as the phar­ma gi­ant twists in the pub­lic spot­light

4 years ago
Bioregnum
Pharma

Re­silience moves Cana­di­an site in­to plas­ma ther­a­pies, as it signs deal with Take­da

4 years ago
Manufacturing
First page Previous page 571572573574575576577 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times